NASDAQ: DICE

Pharmaceutical giant Eli Lilly (NYSE: LLY) has successfully concluded the purchase of US-based Dice Therapeutics (NASDAQ: DICE) by acquiring 88.4% of the company’s issued and outstanding shares in a transaction valued at $2.0 billion. This strategic acquisition allows Lilly to incorporate Dice’s Delscape platform, which is focused on the development…